This study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
290
80 mg/day
San Filippo Neri General Hospital
Rome, Italy, Italy
Major adverse cardiovascular events
The primary end point of the study was prospectively defined as the combination of cardiovascular death, non-fatal acute myocardial re-infarction (re-AMI) and disabling non-fatal stroke.
Time frame: 12 months
Cardiovascular mortality
Time frame: 12 months
Non-fatal acute myocardial re-infarction (re-AMI)
Time frame: 12 months
Disabling non-fatal stroke
Time frame: 12 months
New-onset heart failure
Time frame: 12 months
Atrial fibrillation
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.